Subcutaneous anti-CD20 antibody treatment delays gray matter atrophy in human myelin oligodendrocyte glycoprotein-induced EAE mice


Journal article


Suyog U. Pol, Serena Liang, F. Schweser, Ravendra Dhanraj, A. Schubart, Marilena Preda, M. Sveinsson, D. Ramasamy, M. Dwyer, G. Weckbecker, R. Zivadinov
Experimental Neurology, 2020

Semantic Scholar DOI PubMed
Cite

Cite

APA
Pol, S. U., Liang, S., Schweser, F., Dhanraj, R., Schubart, A., Preda, M., … Zivadinov, R. (2020). Subcutaneous anti-CD20 antibody treatment delays gray matter atrophy in human myelin oligodendrocyte glycoprotein-induced EAE mice. Experimental Neurology.

Chicago/Turabian
Pol, Suyog U., Serena Liang, F. Schweser, Ravendra Dhanraj, A. Schubart, Marilena Preda, M. Sveinsson, et al. “Subcutaneous Anti-CD20 Antibody Treatment Delays Gray Matter Atrophy in Human Myelin Oligodendrocyte Glycoprotein-Induced EAE Mice.” Experimental Neurology (2020).

MLA
Pol, Suyog U., et al. “Subcutaneous Anti-CD20 Antibody Treatment Delays Gray Matter Atrophy in Human Myelin Oligodendrocyte Glycoprotein-Induced EAE Mice.” Experimental Neurology, 2020.